



July 10, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2016-003592-21 / Novartis Protocol ID CAIN457AGB02

Evaluation of the effect of early initiation of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis Requiring Systemic Treatment (FIRST)

Trial CAIN457AGB02 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system as changed to July 1 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.